About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNPhase 1NCT00538538

Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)

Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor. The Submacular Surgery Trial (SST) showed that no stati...

Lead sponsor: Corewell Health East•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Corewell Health East

Subjects will be followed for a period of 12 months. Based on photographs and other testing procedures, if it is deemed in the subject's best interest, the subject may receive monthly injections of Lucentis to help treat the AMD.

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age over 50 years
•Vision 20/200 or worse
•AMD with submacular hemorrhage
•Hemorrhage more than 25% of the lesion
•Fibrosis or scar not more than 25% of the entire lesion
•Hemorrhage less than 3 months old
•Vision loss occuring within 3 months

Exclusion Criteria

•Pregnancy
•Participating in any other clinical trial
•Prior treatment for AMD
•Other medical conditions causing compromised vision
•Intraocular eye surgery within the previous 12 months
•Inability to obtain necessary eye photographs
•Systemic use of anti-VEGF agents
•Allergy to fluorescein dye
•Unable to complete all study visits
•Glaucoma filtering surgery
•Use of 2 or more treatments for glaucoma
•Lack of lens in the eye or absence of a posterior capsule

Related studies

National Eye Institute Biorepository for Retinal Diseases

NCT01496625 · Age-Related Macular Degeneration, Diabetic Retinopathy, and more

RECRUITINGPhase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269 · Geographic Atrophy Secondary to Age-related Macular Degeneration

RECRUITINGPhase 1/2

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

NCT07587515 · Neovascular (Wet) Age-Related Macular Degeneration

RECRUITINGPhase 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05803785 · Age-Related Macular Degeneration

RECRUITINGEARLY Phase 1

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

NCT06593405 · Age-Related Macular Degeneration

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2016Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE1

Enrollment—

Start dateSep 2007

Last updatedAug 8, 2016

Condition

Retinal Hemorrhage Macular Degeneration

Locations shown

William Beaumont Hospital

Royal Oak, Michigan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2016Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions